The value of these mergers will really be dependent on how rapidly and effectively they can change the retail pharmacy setting, said Dan Mendelson, MPP, founder, Avalere Health.
The value of these mergers will really be dependent on how rapidly and effectively they can change the retail pharmacy setting, said Dan Mendelson, MPP, founder, Avalere Health.
TranscriptWhat concerns or expectations do you have for cross-sector mergers like the one between CVS and Aetna?
I think that the value of these mergers will really be dependent on how rapidly and effectively they can change the retail pharmacy setting. The retail pharmacy setting right now, as I said, is not one that is conducive to profitability. It also has so much potential, because the reality is patients trust their pharmacists more than they trust their doctors, more than they trust pretty much anybody else, certainly more than they trust the pharmaceutical company. So, when you look at trust, pharmacists, they rank up there.
So, it’s a setting in which you have a really trusted healthcare professional and pharmacists are really not being fully deployed. The other thing that I think holds a lot of potential is the ability to deliver data at the pharmacy level. The pharmacist should know more about the patient. The pharmacist should know, for example, whether the patient needs a mammogram or not, or whether the patient has gone in to have his cholesterol checked or whether the patient has had a colonoscopy, if the patient needs one.
Right now, the pharmacist doesn’t know that, so getting data, information, and really the ability to engage with patients to the pharmacy counter can really improve the value of what is being delivered in that setting. So, I think that as I look at the combinations, at the business combinations, their ability to really change and leverage in those kinds of value propositions will determine how effective they are.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More